THERAPY DOSSIER · th-674552bbd21a

Picroside II

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28078024 ↗2016Reported benefit

Neuroprotective effect of picroside II in brain injury in mice.

MouseTBIUnspecified20 mg/kg

Model: Four murine brain injury models: traumatic, ischaemic and infectious brain injury

Picroside II at 20 mg/kg improved survival and reduced apoptosis-related proteins, Caspase-3 and acute inflammatory cytokines across traumatic, ischaemic and infectious brain injury models, with downregulation of TLR4 and NF-kappaB. Picroside II alone had no effect.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…